EGFR and neoplasm: Preclinical studies using various agents targeting EGFR, such as gefitinib, lapatinib and anti-EGFR monoclonal antibodies (cetuximab or mimotuzumab), have shown significant antitumor activity against WSCC tumor cell overexpression in EGFR.